BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 30731179)

  • 1. The response to treatment in chronic spontaneous urticaria depends on how it is measured.
    Weller K; Church MK; Metz M; Hawro T; Ohanyan T; Staubach P; Maurer M
    J Allergy Clin Immunol Pract; 2019; 7(6):2055-2056.e4. PubMed ID: 30731179
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of omalizumab in chronic spontaneous urticaria associated with chronic inducible urticaria.
    Dortas Junior S; Azizi G; Valle S
    Ann Allergy Asthma Immunol; 2020 Oct; 125(4):486-487. PubMed ID: 32544531
    [No Abstract]   [Full Text] [Related]  

  • 3. Use of omalizumab in uncontrolled chronic spontaneous urticaria also improved latex-induced contact urticaria.
    Di Leo E; Calogiuri G; Macchia L; Nettis E
    J Allergy Clin Immunol Pract; 2019 Jan; 7(1):300-302. PubMed ID: 29802908
    [No Abstract]   [Full Text] [Related]  

  • 4. Serum transglutaminase 2 activity as a potential biomarker of disease severity and response to omalizumab in chronic spontaneous urticaria.
    Bae Y; Kang SH; Park JO; Park GH; Choi JH
    Allergol Int; 2020 Apr; 69(2):304-306. PubMed ID: 31767272
    [No Abstract]   [Full Text] [Related]  

  • 5. Omalizumab for chronic urticaria in children younger than 12 years.
    Al-Shaikhly T; Rosenthal JA; Ayars AG; Petroni DH
    Ann Allergy Asthma Immunol; 2019 Aug; 123(2):208-210.e2. PubMed ID: 31082483
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy of omalizumab for extracutaneous symptoms of chronic spontaneous urticaria.
    Belbezier A; Boccon-Gibod I; Bouillet L
    Eur J Dermatol; 2021 Feb; 31(1):86-87. PubMed ID: 33772528
    [No Abstract]   [Full Text] [Related]  

  • 7. The use of omalizumab for treatment-refractory chronic spontaneous urticaria in a West Australian outpatient cohort.
    Farrah G; Stevenson B; Lie K; Brusch A
    Intern Med J; 2019 Apr; 49(4):526-528. PubMed ID: 30957371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omalizumab is effective in patients with chronic spontaneous urticaria plus multiple chronic inducible urticaria.
    Skander D; Allenova A; Maurer M; Kolkhir P
    Eur Ann Allergy Clin Immunol; 2021 Mar; 53(2):91-93. PubMed ID: 32496030
    [No Abstract]   [Full Text] [Related]  

  • 9. H1-Antihistamines May No Longer Be Necessary for Patients With Refractory Chronic Spontaneous Urticaria After Initiation of Omalizumab.
    Ensina LF; Arruda LK; Campos RA; Criado RF; Rodrigues Valle S; Melo JM; Oliveira JC; Dortas JS; Cusato-Ensina AP; Camelo-Nunes IC; Agondi RC
    J Investig Allergol Clin Immunol; 2020 Apr; 30(2):145-147. PubMed ID: 31762438
    [No Abstract]   [Full Text] [Related]  

  • 10. Characteristics of patients with chronic spontaneous urticaria showing early and complete responses to omalizumab.
    Cho YT; Fu KT; Yang CW; Chu CY
    Ann Allergy Asthma Immunol; 2021 Sep; 127(3):394-395. PubMed ID: 34102302
    [No Abstract]   [Full Text] [